ODS Cytometric Diagnostics

The future of AI-assisted, low-impact cancer diagnostics starts here

What we do
Diagnostic DNA-Caryometry

AI-Assisted, low-impact microscopical cancer diagnostics

  • Non invasive – Samples can be obtained through brush biopsy, body fluids, or fine needle aspirations

  • AI assisted – Swift computer analysis of cell-nuclei speeds up the workflow, doctors can focus on final confirmation

  • Early diagnosis – DNA-Cytomety / -Caryometry can detect cancers up to 2 years earlier than histopathological methods

Scientific Background

Diagnostic and prognostic cytometry, resp. DNA-karyometry is based on the chromosomal theory of carcinogenesis, developed by Boveri and von Hansemann which postulated that chromosomal chaos was the reason for aberrant chromatin structure, seen in cancer cells. Since then, chromosomal aneuploidy has been linked to nearly all cases of cancer.

  • Caryotype – shows a set of chromosomes, a pair is called a diploid set. Euploid means all the chromosomes are structurally intact and in matched pair sets whereas aneuploid karyotypes contain chromosomes that are not in matched pair sets (missing or additional).

  • Reproduction of chromosomal aneuploidy – normally when a cell makes a reproduction error the cell will be non-viable but sometimes this aberrant cell will still be able to divide and pass on its aneuploidy.

  • Aneuploidy and cancer – this single error often leads to more errors in the future and causes a snowball effect. As time goes on this leads to the cell becoming cancer.

  • Cytometry – Detecting DNA-aneuploidy means that there is cancer, a malignant tumour, or that it is highly likely that the lesion will develop into cancer or a malignant tumour in the future. DNA-aneuploidy is the cytometric equivalent of chromosomal aneuploidy.

The Team

Prof. Alfred Boecking
Prof. Alfred Boecking
Prof. Böcking was Head of Cytopathology at the University Hospital of Düsseldorf from 1994 to 2009. He also held the position of President of the European Society for Analytical Cellular Pathology from 1995 to 1998. He is one of the key pioneers in Cytopathology and Image based Cytometry. Today Prof. Böcking is CTO of Objective Diagnostics Systems Inc.
Dr. Branko Palcic
Dr. Branko Palcic
Dr. Branko Palcic was the founder and Head of BC Cancer’s Cancer Imaging Department from 1995 to 2001. He is a key pioneer in Image based Cythometry cancer screening. He served as Director of Technology Development for BC Cancer Agency until 2002. Today Dr. Branko is Co- founder and CEO of Objective Diagnostic Systems Inc.

Application in cancer diagnostics

Screening

Early Diagnosis

(assessment of dysplasia)

Prognosis

  • Cells in oral smears

  • Cells in cervical smears

  • Cells in bronchial secretions

  • Cells in effusions

  • Cells in urines

  • Oral cancer

  • Cervical cancer

  • Bladder cancer

  • Cancers of anus

  • Bronchial cancer

  • Prostate cancers

Diagnostic technology

Enter the world of diagnostic technology and learn more about DNA-Caryometry